source
- BioNTech's gotistobart shows 18.5-month median survival in relapsed squamous lung cancer, beating docetaxelBioNTech presented updated data from its phase 3 Preserve-003 trial at the World Conference on Lung Cancer in Seoul. The trial compares its anti-CTLA-4 antibody gotistobart with standard chemothera…
- Frazier Life Sciences raises over $1.1 billion for its public biotech fund, now $2.8 billion totalFrazier Life Sciences announced that its public fund has secured more than $1.1 billion in new capital, bringing the fund’s total assets to $2.8 billion. The fund, launched in 2021, targets small-…Fierce Biotech · 4d agoDealPositive